EXPEDITED REVIEW
Pathology of Drug-Eluting Stents in Humans
Delayed Healing and Late Thrombotic Risk
Michael Joner, MD*,1,
Aloke V. Finn, MD ,1,
Andrew Farb, MD ,
Erik K. Mont, MD ,
Frank D. Kolodgie, PhD*,
Elena Ladich, MD*,
Robert Kutys, MS*,
Kristi Skorija, BS*,
Herman K. Gold, MD and
Renu Virmani, MD*,*
* CVPath, International Registry of Pathology, Gaithersburg, Maryland
Cardiac Unit, Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
Miami Dade County Medical Examiner Department, Heart Radiology, Miami, Florida
Interventional Cardiology Devices Branch, U.S. Food and Drug Administration, Rockville, Maryland
Manuscript received January 26, 2006;
revised manuscript received March 10, 2006,
accepted March 16, 2006.
* Reprint requests and correspondence: Dr. Renu Virmani, CVPath, International Registry of Pathology, 19 Firstfield Road, Gaithersburg, Maryland 20878 (Email: rvirmani{at}cvpath.org).
OBJECTIVES: This study examined human drug-eluting stents (DES) to determine the long-term effects of these stents on coronary arterial healing and identified mechanisms underlying late stent thrombosis (LST).
BACKGROUND: Although DES reduce the need for repeat revascularization compared with bare-metal stents (BMS), data suggest the window of thrombotic risk for Cypher (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) DES extends far beyond that for BMS.
METHODS: From a registry of 40 autopsies of DES (68 stents), 23 DES cases of >30 days duration were compared with 25 matched autopsies of BMS implantation. Late stent thrombosis was defined as an acute thrombus within a stent >30 days old.
RESULTS: Of 23 patients with DES >30 days old, 14 had evidence of LST. Cypher and Taxus DES showed greater delayed healing characterized by persistent fibrin deposition (fibrin score 2.3 ± 1.1 vs. 0.9 ± 0.8, p = 0.0001) and poorer endothelialization (55.8 ± 26.5%) compared with BMS (89.8 ± 20.9, p = 0.0001). Moreover, DES with LST showed more delayed healing compared with patent DES. In 5 of 14 patients suffering LST, antiplatelet therapy had been withdrawn. Additional procedural and pathologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation stenting; 3) malapposition/incomplete apposition; 4) restenosis; and 5) strut penetration into a necrotic core.
CONCLUSIONS: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration. The cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
|
Abbreviations and Acronyms
| | BMS = bare-metal stents | | DES = drug-eluting stents | | FDA = Food and Drug Administration | | LST = late stent thrombosis |
|
This article has been cited by other articles:
|
|
|
|
 
American College of Cardiology Foundation, American Heart Association Task Force on Practice, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine, Society for Vascular Surgery, L. A. Fleisher, et al.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
J. Am. Coll. Cardiol.,
November 24, 2009;
54(22):
e13 - e118.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A.M. Beijk, M. Klomp, N. J.W. Verouden, N. van Geloven, K. T. Koch, J. P.S. Henriques, J. Baan, M. M. Vis, E. Scheunhage, J. J. Piek, et al.
GenousTM endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study
Eur. Heart J.,
November 18, 2009;
(2009)
ehp476v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nakazawa, A. V. Finn, M. Vorpahl, E. Ladich, R. Kutys, I. Balazs, F. D. Kolodgie, and R. Virmani
Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis.
J. Am. Coll. Cardiol.,
November 17, 2009;
54(21):
1924 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Carter
Drug-eluting stent fracture promise and performance.
J. Am. Coll. Cardiol.,
November 17, 2009;
54(21):
1932 - 1934.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, M. John, G. Nakazawa, R. Polavarapu, V. Karmali, X. Xu, Q. Cheng, T. Davis, C. Raghunathan, E. Acampado, et al.
Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor {gamma} Agonists: Requirement for mTOR/Akt2 in PPAR{gamma} Activation
Circ. Res.,
November 6, 2009;
105(10):
1003 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Barlis, E. Regar, P. W. Serruys, K. Dimopoulos, W. J. van der Giessen, R.-J. M. van Geuns, G. Ferrante, S. Wandel, S. Windecker, G.-A. van Es, et al.
An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study
Eur. Heart J.,
November 4, 2009;
(2009)
ehp480v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al.
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Eur. Heart J.,
November 2, 2009;
30(22):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Byrne, A. Kastrati, S. Kufner, S. Massberg, K. A. Birkmeier, K.-L. Laugwitz, S. Schulz, J. Pache, M. Fusaro, M. Seyfarth, et al.
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial
Eur. Heart J.,
October 2, 2009;
30(20):
2441 - 2449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Kugelmass
The quest for a 'better mousetrap'
Eur. Heart J.,
October 2, 2009;
30(20):
2431 - 2432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. T. Meredith, S. Worthley, R. Whitbourn, D. L. Walters, D. McClean, M. Horrigan, J. J. Popma, D. E. Cutlip, A. DePaoli, M. Negoita, et al.
Clinical and Angiographic Results With the Next-Generation Resolute Stent System: A Prospective, Multicenter, First-in-Human Trial
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
977 - 985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis
A Generation 2.5 Drug-Eluting Stent?
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
986 - 988.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Sera, M. Awata, M. Uematsu, J.-i. Kotani, S. Nanto, and S. Nagata
Optimal Stent-Sizing With Intravascular Ultrasound Contributes to Complete Neointimal Coverage After Sirolimus-Eluting Stent Implantation Assessed by Angioscopy
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
989 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Mintz and S.-Y. Choi
Optimal Stent Expansion and Complete Neointimal Coverage: Does This Association Make Sense?
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
995 - 996.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ormiston, M. W.I. Webster, R. S. Schwartz, P. Gladding, J. T. Stewart, I. P. Kay, P. N. Ruygrok, and R. Hatrick
Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus-Eluting Stent: Traditional Pre-Clinical Safety End Points Failed to Predict 6-Month Clinical Angiographic Results
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
1017 - 1024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-e. Obata, T. Nakamura, Y. Kitta, Y. Kodama, K. Sano, K.-I. Kawabata, Y. Saitoh, D. Fujioka, T. Kobayashi, T. Yano, et al.
Treatment of Acute Myocardial Infarction With Sirolimus-Eluting Stents Results in Chronic Endothelial Dysfunction in the Infarct-Related Coronary Artery
Circ Cardiovasc Interv,
October 1, 2009;
2(5):
384 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Toutain, C. Filipe, A. Billon, C. Fontaine, L. Brouchet, J.-C. Guery, P. Gourdy, J.-F. Arnal, and F. Lenfant
Estrogen Receptor {alpha} Expression in Both Endothelium and Hematopoietic Cells Is Required for the Accelerative Effect of Estradiol on Reendothelialization
Arterioscler Thromb Vasc Biol,
October 1, 2009;
29(10):
1543 - 1550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R A Byrne, S Kufner, K Tiroch, S Massberg, K-L Laugwitz, A Birkmeier, S Schulz, J Mehilli, and for the Intracoronary Stenting and Angiographic Re
Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results
Heart,
September 15, 2009;
95(18):
1489 - 1494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al.
Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study
Eur. Heart J.,
September 1, 2009;
30(17):
2095 - 2101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Wykrzykowska, P. W. Serruys, Y. Onuma, T. de Vries, G.-A. van Es, P. Buszman, A. Linke, T. Ischinger, V. Klauss, R. Corti, et al.
Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer: The LEADERS Trial Substudy
J. Am. Coll. Cardiol. Intv.,
September 1, 2009;
2(9):
861 - 870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Luckie, R S Khattar, and D Fraser
Non-cardiac surgery and antiplatelet therapy following coronary artery stenting
Heart,
August 15, 2009;
95(16):
1303 - 1308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cook, E. Ladich, G. Nakazawa, P. Eshtehardi, M. Neidhart, R. Vogel, M. Togni, P. Wenaweser, M. Billinger, C. Seiler, et al.
Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis
Circulation,
August 4, 2009;
120(5):
391 - 399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cook and P. Wenaweser
Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
273 - 276.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, G. Nakazawa, F. Kolodgie, and R. Virmani
Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?
Eur. Heart J.,
August 1, 2009;
30(15):
1828 - 1830.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Waseda, A. Miyazawa, J. Ako, T. Hasegawa, I. Tsujino, R. Sakurai, P. G. Yock, Y. Honda, D. E. Kandzari, M. B. Leon, et al.
Intravascular Ultrasound Results From the ENDEAVOR IV Trial: Randomized Comparison Between Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
779 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Wilson, G. Nakazawa, R. S. Schwartz, B. Huibregtse, B. Poff, T. J. Herbst, D. S. Baim, and R. Virmani
Comparison of Inflammatory Response After Implantation of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries
Circulation,
July 14, 2009;
120(2):
141 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Drachman
Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today?
Circulation,
July 14, 2009;
120(2):
101 - 103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis
Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
J. Am. Coll. Cardiol. Intv.,
July 1, 2009;
2(7):
583 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ota, M. Eto, J. Ako, S. Ogawa, K. Iijima, M. Akishita, and Y. Ouchi
Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
J. Am. Coll. Cardiol.,
June 16, 2009;
53(24):
2298 - 2305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, G. S. Werner, D. Antoni, F. X. Kleber, W. Bocksch, et al.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Circulation,
June 16, 2009;
119(23):
2986 - 2994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Alfonso, M.-J. Perez-Vizcayno, M. Ruiz, A. Suarez, M. Cazares, R. Hernandez, J. Escaned, C. Banuelos, P. Jimenez-Quevedo, and C. Macaya
Coronary aneurysms after drug-eluting stent implantation clinical, angiographic, and intravascular ultrasound findings.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2053 - 2060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Onuma, P. Serruys, P. den Heijer, K. S. Joesoef, H. Duckers, E. Regar, N. Kukreja, S. Tanimoto, H. M. Garcia-Garcia, H. van Beusekom, et al.
MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses
Eur. Heart J.,
June 2, 2009;
30(12):
1477 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ormiston and P. W.S. Serruys
Bioabsorbable Coronary Stents
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
255 - 260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Niccoli, D. Schiavino, F. Belloni, G. Ferrante, G. La Torre, M. Conte, N. Cosentino, R. A. Montone, V. Sabato, F. Burzotta, et al.
Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents
Eur. Heart J.,
June 1, 2009;
30(11):
1340 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takemoto, H. Kawata, T. Soeda, K. Imagawa, S. Somekawa, Y. Takeda, S. Uemura, M. Matsumoto, Y. Fujimura, J.-i. Jo, et al.
Human Placental Ectonucleoside Triphosphate Diphosphohydrolase Gene Transfer via Gelatin-Coated Stents Prevents In-Stent Thrombosis
Arterioscler Thromb Vasc Biol,
June 1, 2009;
29(6):
857 - 862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chevalier, S. Silber, S.-J. Park, E. Garcia, G. Schuler, H. Suryapranata, J. Koolen, K. E. Hauptmann, W. Wijns, M.-C. Morice, et al.
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial--Phase 2
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nakazawa, M. Vorpahl, A. V. Finn, J. Narula, and R. Virmani
One step forward and two steps back with drug-eluting-stents from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.
J. Am. Coll. Cardiol. Img.,
May 1, 2009;
2(5):
625 - 628.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Suzuki, A. C. Yeung, and F. Ikeno
The Pre-Clinical Animal Model in the Translational Research of Interventional Cardiology
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
373 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moore, P. Barlis, J. Spiro, G. Ghimire, M. Roughton, C. Di Mario, W. Wallis, C. Ilsley, A. Mitchell, M. Mason, et al.
A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
437 - 444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Gonzalo, P. Barlis, P. W. Serruys, H. M. Garcia-Garcia, Y. Onuma, J. Ligthart, and E. Regar
Incomplete Stent Apposition and Delayed Tissue Coverage Are More Frequent in Drug-Eluting Stents Implanted During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Than in Drug-Eluting Stents Implanted for Stable/Unstable Angina: Insights From Optical Coherence Tomography
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
445 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-J. Lee, A. Hinek, R. R. Chaturvedi, C. L. Almeida, O. Honjo, G. Koren, and L. N. Benson
Rapamycin-Eluting Stents in the Arterial Duct: Experimental Observations in the Pig Model
Circulation,
April 21, 2009;
119(15):
2078 - 2085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Calvert and M. R. Bennett
Restenosis Revisited
Circ. Res.,
April 10, 2009;
104(7):
823 - 825.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Byrne, J. Mehilli, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, A. Schomig, A. Kastrati, and for the Intracoronary Stenting and Angiographic Re
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents
Eur. Heart J.,
April 2, 2009;
30(8):
923 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. van der Giessen, O. Sorop, P. W. Serruys, I. Peters-Krabbendam, and H. M.M. van Beusekom
Lowering the Dose of Sirolimus, Released From a Nonpolymeric Hydroxyapatite Coated Coronary Stent, Reduces Signs of Delayed Healing
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
284 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, G. Nakazawa, F. D. Kolodgie, and R. Virmani
Temporal Course of Neointimal Formation After Drug-Eluting Stent Placement: Is Our Understanding of Restenosis Changing?
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
300 - 302.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Waksman, R. Erbel, C. Di Mario, J. Bartunek, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, M. Horrigan, C. Ilsley, et al.
Early- and Long-Term Intravascular Ultrasound and Angiographic Findings After Bioabsorbable Magnesium Stent Implantation in Human Coronary Arteries
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
312 - 320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Samady, M. McDaniel, E. Veledar, B. De Bruyne, N. H. Pijls, W. F. Fearon, and V. Vaccarino
Baseline Fractional Flow Reserve and Stent Diameter Predict Optimal Post-Stent Fractional Flow Reserve and Major Adverse Cardiac Events After Bare-Metal Stent Deployment
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
357 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Pendyala, J. Li, T. Shinke, S. Geva, X. Yin, J. P. Chen, S. B. King III, K. A. Robinson, N. A.F. Chronos, and D. Hou
Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative Stress
J. Am. Coll. Cardiol. Intv.,
March 1, 2009;
2(3):
253 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker and P. Juni
The Drug-Eluting Stent Saga
Circulation,
February 10, 2009;
119(5):
653 - 656.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Aoki, A. J. Lansky, R. Mehran, J. Moses, M. E. Bertrand, B. T. McLaurin, D. A. Cox, A. M. Lincoff, E. M. Ohman, H. D. White, et al.
Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial
Circulation,
February 10, 2009;
119(5):
687 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Stahli, G. G. Camici, and F. C. Tanner
Drug-eluting stent thrombosis
Therapeutic Advances in Cardiovascular Disease,
February 1, 2009;
3(1):
45 - 52.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Ph. G. Steg, K. A.A. Fox, K. A. Eagle, M. Furman, F. Van de Werf, G. Montalescot, S. G. Goodman, A. Avezum, W. Huang, J. M. Gore, et al.
Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events
Eur. Heart J.,
February 1, 2009;
30(3):
321 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K.M. Hassan, S. C. Bergheanu, T. Stijnen, B. L. van der Hoeven, J. D. Snoep, J. W.M. Plevier, M. J. Schalij, and J. W. Jukema
Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis
Eur. Heart J.,
January 21, 2009;
(2009)
ehn553v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Philpott MD, D. A. Southern MSc, F. M. Clement PhD, P. D. Galbraith BN MSc, M. Traboulsi MD, M. L. Knudtson MD, W. A. Ghali MD, and for the APPROACH Investigators
Long-term outcomes of patients receiving drug-eluting stents
Can. Med. Assoc. J.,
January 20, 2009;
180(2):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/writing members:, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
Eur. Heart J.,
January 2, 2009;
30(2):
152 - 161.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J.,
January 1, 2009;
30(1):
16 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Di Mario, G. R. Heyndrickx, F. Prati, and N. H.J. Pijls
CHAPTER 8 Invasive Imaging and Haemodynamics
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Shemin
Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof?
Circulation,
December 2, 2008;
118(23):
2326 - 2329.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hamilos, J. Sarma, M. Ostojic, T. Cuisset, G. Sarno, N. Melikian, A. Ntalianis, O. Muller, E. Barbato, B. Beleslin, et al.
Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
193 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Chhatriwalla and D. L. Bhatt
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
217 - 225.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and R. T. Gerber
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
226 - 232.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Adriaenssens, R. A. Byrne, A. Dibra, R. Iijima, J. Mehilli, O. Bruskina, A. Schomig, and A. Kastrati
Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes
Eur. Heart J.,
December 1, 2008;
29(23):
2868 - 2876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Joner, K. Morimoto, H. Kasukawa, K. Steigerwald, S. Merl, G. Nakazawa, M. C. John, A. V. Finn, E. Acampado, F. D. Kolodgie, et al.
Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma
Arterioscler Thromb Vasc Biol,
November 1, 2008;
28(11):
1960 - 1966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F. D. Kolodgie, H. K. Gold, et al.
Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
535 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kukreja, Y. Onuma, H. Garcia-Garcia, J. Daemen, R. van Domburg, and P. W. Serruys
Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation
Circ Cardiovasc Interv,
October 1, 2008;
1(2):
103 - 110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al.
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1134 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Pfisterer
Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised
Circulation,
September 9, 2008;
118(11):
1117 - 1119.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kelbaek, L. Thuesen, S. Helqvist, P. Clemmensen, L. Klovgaard, A. Kaltoft, B. Andersen, H. Thuesen, T. Engstrom, H. E. Botker, et al.
Drug-Eluting Versus Bare Metal Stents in Patients With ST-Segment-Elevation Myocardial Infarction: Eight-Month Follow-Up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) Trial
Circulation,
September 9, 2008;
118(11):
1155 - 1162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nakazawa, A. V. Finn, M. Joner, E. Ladich, R. Kutys, E. K. Mont, H. K. Gold, A. P. Burke, F. D. Kolodgie, and R. Virmani
Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study
Circulation,
September 9, 2008;
118(11):
1138 - 1145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yau, P. Molnar, M. C. Moon, S. Buhay, J. P. Werner, K. Molnar, L. Saward, D. Del Rizzo, and P. Zahradka
meta-Iodobenzylguanidine, an Inhibitor of Arginine-Dependent Mono(ADP-ribosyl)ation, Prevents Neointimal Hyperplasia
J. Pharmacol. Exp. Ther.,
September 1, 2008;
326(3):
717 - 724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O C Raffel, T Akasaka, and I-K Jang
Cardiac optical coherence tomography
Heart,
September 1, 2008;
94(9):
1200 - 1210.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M. C. Morice, A. Schomig, M. E Pfisterer, G. W Stone, M. B Leon, J. S. d. Lezo, et al.
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
BMJ,
August 29, 2008;
337(aug29_3):
a1331 - a1331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al.
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Eur. Heart J.,
August 2, 2008;
29(16):
1975 - 1982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Abbott
Revealing the Silver and Red Lining in Drug-Eluting Stents With Angioscopy
Circ Cardiovasc Interv,
August 1, 2008;
1(1):
7 - 9.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Takano, M. Yamamoto, D. Murakami, S. Inami, K. Okamatsu, K. Seimiya, T. Ohba, Y. Seino, and K. Mizuno
Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents
Circ Cardiovasc Interv,
August 1, 2008;
1(1):
20 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Shinke, J. Li, J. P. Chen, L. Pendyala, T. Goodchild, R. Jabara, S. Geva, T. Ueno, N. Chronos, K. Robinson, et al.
High Incidence of Intramural Thrombus After Overlapping Paclitaxel-Eluting Stent Implantation: Angioscopic and Histopathologic Analysis in Porcine Coronary Arteries
Circ Cardiovasc Interv,
August 1, 2008;
1(1):
28 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: II. Perioperative Considerations and Management
Anesth. Analg.,
August 1, 2008;
107(2):
570 - 590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Joner, G. Nakazawa, A. V. Finn, S. C. Quee, L. Coleman, E. Acampado, P. S. Wilson, K. Skorija, Q. Cheng, X. Xu, et al.
Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents
J. Am. Coll. Cardiol.,
July 29, 2008;
52(5):
333 - 342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Alfonso
The "vulnerable" stent why so dreadful?
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2403 - 2406.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sullivan and N. Amarshi
Dual antiplatelet therapy with clopidogrel and aspirin
Am. J. Health Syst. Pharm.,
June 15, 2008;
65(12):
1134 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I.-L. A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A. Y.-J. Shen
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
J. Am. Coll. Cardiol.,
June 10, 2008;
51(23):
2220 - 2227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-H. Choi, A. Prasad, and S. Tsimikas
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
J. Am. Coll. Cardiol.,
June 10, 2008;
51(23):
2228 - 2229.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, et al.
Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2123 - 2129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Shishehbor, R. Amini, L. P.J. Oliveria, I. M. Singh, P. Kelly, D. L. Bhatt, S. R. Kapadia, S. G. Ellis, P. L. Whitlow, and S. J. Brener
Comparison of Drug-Eluting Stents Versus Bare-Metal Stents for Treating ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
227 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
